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336 Is there any difference in nutritional status between CF patients
with and without liver disease
L. Spirevska1, S. Fustik1, T. Jakovska1. 1Pediatric Clinic, Skopje, Macedonia, the
Former Yugoslav Republic of
Patients with cystic ﬁbrosis (CF) are predisposed to develop liver disease (LD). The
aim of the study was to compare the growth status of CF patients with and without
chronic liver disease.
Material and Methods: The study included seventy-eight CF patients above
3 years who regularly attend our CF Center. We examined the results from the last
antropometric measurements. Group one consisted of 21 CF patients with chronic
hepatic disease (mean age 15.3±4.7, 13 boys) and a control group consisted of
28 CF patients without hepatic disease (mean age 10.4±6.4, 37 boys). LD was
deﬁned by the ﬁnding the hepatomegaly, signiﬁcant or persistent increased serum
hepatic enzyme levels, ultrasonographic abnormalities (score >4) and morphologic
or functional scintigraphic abnormalities. Nutritional status was evaluated based on
anthropometric assessment: height for age z-score, weight for age z-score, z-score
weight for height and body mass index. Statistical comparisons between the groups
were performed using Student t-test. The difference was considered signiﬁcant at
p< 0.05.
Results: Mean values and SD for CF patients with LD were ZH=−0.75±0.97,
ZW=0.57±0.65, ZW/H= 0.13±0.52, BMI = 18.8±1.85. Mean values and SD
for CF patients without LD were ZH=−0.51±1.21, ZW=0.44±1.33, ZW/H=
0.12±1.09, BMI = 17.3±2.10. There wasn’t any signiﬁcant difference between the
groups (p> 0.05).
There weren’t any differences in the anthropometric measurements between our
CF patients with chronic liver disease and without liver disease. We can conclude
that chronic hepatic disease hasn’t any inﬂuence on the nutritional status in
CF patients.
337 Overweight/obese CF patients, cause for concern?
M. Rezaie1, L. Speight1, J. Duckers1, R.I. Ketchell1. 1University Hospital
Llandough, Adult Cystic Fibrosis Centre, Penarth, United Kingdom
Aim: To look at all our adult CF patients with a BMI> 25 to establish if there was
any clinical implications to their future management and well-being.
Method: A review of the BMI of all patients attending the all Wales Adult
CF Centre assessing age, diabetic status, lipid proﬁle, pancreatic status, FEV1 and
genotype in those with a BMI> 25 over a 3 yr period (2007–2009).
Results: 35 (18%) of 193 patients had a BMI> 25, mean age of these patients
was 31 (range 18−51), 63% Male, 34% DF508 homozygous. 29% had an elevated
Cholesterol (>5.0) and 23% had elevated Triglycerides (>2.0). 31% were pancreatic
sufﬁcient. 6/35 had CFRD and 2 had IGT. 4/35 (11%) had an FEV1 < 50%,
2/35 <30%. All 35 were given basic individual weight reducing advice; those
with abnormal lipids were treated appropriately and given dietary advice. 1 patient
(BMI> 34) was given a target weight loss and exercise programme prior to referral
for transplant assessment. 7/35 patients had a reduction in BMI since receiving
weight reducing advice.
Conclusion: Overweight patients tended to be older with better lung function than
our general patient population. However, an aging CF population with an increased
incidence of CFRD and dyslipidaemia with a high BMI will ultimately lead to
associated health complications. A proactive approach advising weight loss/healthy
eating and increased exercise has been introduced in these CF patients. However,
there is a ﬁne line between quality of life and increased treatment needs; ultimately,
should we add to the burden of treatment, especially in those >75% lung function
(51%) with no other signiﬁcant health complications.
338 Evaluation of growth in peri-pubertal cystic ﬁbrosis (CF) subjects
with exocrine pancreatic insufﬁciency (EPI) treated with the novel
non-porcine pancreatic enzyme replacement therapy liprotamase
C. Stevens1, L. Breetman1, M. Campion1, D. Borowitz2. 1Alnara Pharmaceuticals,
Cambridge, MA, United States; 2State University of New York at Buffalo, Buffalo,
MA, United States
Background and Aims: A 12-month, open-label, safety and clinical activity
study of liprotamase, a non-porcine pancreatic enzyme replacement therapy was
conducted in patients with CF and EPI. The objective of this analysis was to evaluate
trends in weight, height, and body mass index (BMI) in peri-pubertal subjects.
Methods: Clinically stable CF subjects 7 years of age were enrolled, with fecal
elastase <100mg/g of stool. Subjects took one or more capsules of liprotamase
(containing 32,500 units lipase, 25,000 units protease and 3,750 units amylase) in
the middle of 3 meals and 2 snacks each day.
Results: A total of 214 subjects were treated with liprotamase and 55 (25.7%)
of the 214 subjects were 7 to <12 years old and 57 (26.6%) were 12 to <17
years old. For the overall study population, the mean number of capsules per meal
was 5.5. For subjects 7 to <12 years of age, the mean(SD) height z-scores were
−0.464(0.742), −0.491(0.718) and −0.594(0.732) at Months 3, 6 and 12, respectively
with mean(SD) increases in height from baseline of 1.4(0.92), 2.5(1.32), and
4.9(1.54) cm, respectively. Similar analysis for weight and BMI will be presented.
Conclusions: After an initial period of adjustment, weight showed a steady increase
over the 12-month observational period in peri-pubertal subjects with CF-related
EPI treated with liprotamase. Importantly, height growth, which is dependent on
normal nutritional status, increased over the study period. These data support the use
of liprotamase, a non-porcine pancreatic enzyme replacement therapy in growing
children with CF-related EPI.
This study was supported by Alnara Pharmaceuticals Inc. and Cystic Fibrosis
Foundation Therapeutics, Inc.
339* Body composition and lung function in young children with
cystic ﬁbrosis
J.E. Williams1, C. Benden2, A. Jaffe2, R. Suri2, J.C. Wells1, M.S. Fewtrell1. 1UCL
Institute of Child Health, Childhood Nutrition, London, United Kingdom; 2Great
Ormond Street Hospital for Sick Children, Respiratory Medicine, London, United
Kingdom
Objective: Patients with cystic ﬁbrosis (CF) are at risk of malnutrition and studies
have found a relationship between fat-free mass (FFM) and lung function (LF). We
used the ‘gold standard’ four-component model (4CM) to assess body composition
(BC) and related that to LF.
Methods: BC was measured in 85 CF subjects aged 6−12 yrs and results compared
with UK reference data and healthy matched controls. LF (FEV1 %predicted) was
measured and relationships with fat mass (FM) and FFM adjusted for height [FM
and FFM indices (FMI and FFMI)] investigated.
Results: Compared to UK ref data CF boys (n = 37) were shorter [mean(sd)
height sds; −0.5(1.0), p< 0.05] but had higher BMI sds; [0.4(1.0), p< 0.01]; CF girls
were shorter [−0.6(1.0), p< 0.001] with lower BMI sds [−0.3(1.0), p< 0.05].
Compared to matched controls CF boys had greater FFMI sds [0.6(1.0), p< 0.01]
whilst CF girls had lower FMI sds [−0.7(0.9), p< 0.001] and mineral mass index sds
[−0.8(1.1), p< 0.001]. Prepubertal girls (n = 24) had no deﬁcit in mineral. Six
children (5 boys) had BMI sds >95th centile; this was due to increased FM in
4 boys. CF girls had lower FEV1% than boys [mean(sd) 77.6(18.4) v 91.3(20.9),
p< 0.01]. FM was signiﬁcantly related to FEV1% in girls only (p< 0.01) but there
was no association between FFM and LF in either sex.
Conclusion: CF boys had normal BC, whilst girls had lower FM than controls.
Six children had a BMIsds in the obese range but 2 cases were due to high FFM,
not FM. We found no association between FFM and LF. The signiﬁcant positive
association between FM and FEV1% in girls may reﬂect their poorer nutritional
status and this sex difference merits more attention.
